Humana (HUM) is in discussions with billionaire entrepreneur Mark Cuban to form a partnership aimed at streamlining the drug supply chain. This potential collaboration, revealed at the Forbes Healthcare Summit, focuses on developing direct-to-employer programs through Cuban's Cost Plus Drugs. The initiative seeks to bypass traditional pharmacy benefit managers by removing rebates and spread pricing, offering cost savings directly to patients. This move aligns with ongoing industry reforms aimed at addressing regulatory concerns over the role of PBMs, often criticized for their intermediary position in the drug distribution process.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.